Successful low-dose chemotherapy for refractory Epstein-Barr virus-related post-transplant lymphoproliferative disorder following hematopoietic stem cell transplantation in a child with Wiskott-Aldrich syndrome

Bixin Xi; Chen Zhou; Yu Zhang

doi:10.1002/ccr3.4111

Successful low-dose chemotherapy for refractory Epstein-Barr virus-related post-transplant lymphoproliferative disorder following hematopoietic stem cell transplantation in a child with Wiskott-Aldrich syndrome

Clin Case Rep. 2021 May 24;9(5):e04111. doi: 10.1002/ccr3.4111. eCollection 2021 May.

Authors

Bixin Xi¹, Chen Zhou², Yu Zhang³

Affiliations

¹ Department of Paediatrics Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan China.
² Key Laboratory of Paediatric Haematology and Oncology Ministry of Health Department of Haematology and Oncology Shanghai Children's Medical Centre Shanghai Jiao Tong University School of Medicine Shanghai China.
³ Department of Gynaecology Wuhan Children's Hospital (Wuhan Maternal and Child Healthcare Hospital) Tongji Medical College Huazhong University of Science and Technology Wuhan China.

Abstract

We report the first case of a 12-year-old boy with Wiskott-Aldrich syndrome who developed CD20-weakly expressed and CD30-highly expressed Epstein-Barr virus-related post-transplant lymphoproliferative disorder refractory to rituximab treatment. The patient was effectively and safely treated with personalized low-dose chemotherapy and subsequently remained in complete remission for 1 year.

Keywords: Epstein‐Barr virus; Wiskott‐Aldrich syndrome; hematopoietic stem cell transplantation; low‐dose chemotherapy; pediatric; post‐transplant lymphoproliferative disorder; rituximab.

Publication types

Case Reports